Journal of IiME Volume 5 Issue 1 (May 2011) PRESENTERS at the 6th INVEST in ME INTERNATIONAL ME/CFS CONFERENCE Faecal analysis and faecal microbial analysis are very useful in the diagnostic workup. They reveal specific chemical and microbial abnormalities with therapeutic implications. Part II : Treatment and trials of CFS/ME Apart from the use of anti-inflammatory drugs or compounds, antioxidants and certain nutraceuticals and based on laboratory test abnormalities, following elements of therapy are common to the therapy of all ME/CFS patients : 1. individualized diet 2. treatment of dysbiosis (pre-, pro- and antibiotics) 3. use of immunomodulators In specific ME/CFS subgroups, we use antivirals, antimycotic drugs, antibiotics for zoonoses (ILADS protocols) and other directed at specific opportunistic or other infections. Professor Tom Wileman Professor Wileman is Professor of Molecular Virology and Director at the Biomedical Research Centre at the University of East Anglia in Norwich, UK. His previous positions in the UK have included the Head of the Department of Immunology and Pathology at the BBSRC Institute of Animal Health, Pirbright. He was Assistant Professor at the Department of Medicine at Harvard Medical School in Boston, USA where worked at the Dana Farber Cancer Institute and Beth Israel Hospital. He held investigator awards from the Claudia Adam's Barr Foundation for Cancer Research, the Medical Foundation of the Charles King Trust and was Basil O'Connor Scholar of the March of Dimes Research Foundation. Prior to that he was SERC NATO Fellow and Fellow of the Parker Francis Pulmonary Research Foundation within the Department of Cell Biology, Washington University Medical School, St Louis. Professor Simon Carding Professor Simon Carding Professor of Mucosal Immunology at University of East Anglia and Institute of Food Research. Following his PhD at London he held postdoctoral positions at New York University School of Medicine, New York and at Yale University School of Medicine, New Haven, USA. He then moved to the University of Pennsylvania, Philadelphia, USA as Assistant and later Associate Professor. He joined University of Leeds as Professor of Molecular Immunology in the Institute of Molecular and Cellular Biology in 1999. His scientific interests are in understanding how the immune response in the gut functions and in particular, is able to distinguish between the commensal microbes that reside in the gut and environmental microbes that cause disease, and in the mechanisms by which the body‟s immune system no longer ignores or tolerates commensal gut bacteria and how this leads to immune system activation and inflammatory bowel disease. Invest in ME (Charity Nr. 1114035) www.investinme.org Page 51/58

52 Publizr Home

You need flash player to view this online publication